![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
ABSTRACT
Purpose
To describe a case of Vogt-Koyanagi-Harada (VKH) disease after a Covid-19 mRNA vaccine (tozinameran) and to present the results of a pharmacovigilance disproportionality study.
Methods
A retrospective chart review and a pharmacovigilance disproportionality study using the WHO global individual case safety reports database (VigiBase).
Results
A 57-year-old female with no medical history developed a VKH disease 3 weeks after Covid-19 mRNA vaccine. Symptoms at onset were headaches and blurred vision associated with aseptic meningitis and bilateral diffuse granulomatous panuveitis with serous retinal detachment. One month from diagnosis and glucocorticoids treatment, the patient recovered. Five similar cases have been reported in VigiBase. VKH disease is disproportionately reported with tozinameran and other vaccines.
Conclusion
VKH disease is disproportionately reported with tozinameran, suggesting a possible safety signal. Cases after vaccination support the screening for any possible immune triggers such as vaccines when assessing patients with VKH disease.
Acknowledgments
We thank Pierre PILLITTERI, Rafael BOUCHER and Simon CLAUTRIER for their help in patient management and data collection.
Disclosure statement
No potential conflict of interest was reported by the author(s).
Consent for publication
Informed consent was obtained from the patient for publication.
Important notice
This case has been registered in the French pharmacovigilance database under the national number PV20212137. The information from VigiBase comes from a variety of sources, and the probability that the suspected adverse effect is drug-related is not the same in all cases. The information does not represent the opinion of the UMC, the World Health Organization and only reflects the authors’ opinion.